T1D is a disease characterized by a dysregulation of the immune system that destroys the insulin-producing beta cells in the pancreas and leads to subsequent inability to regulate blood sugar levels. Typically, T1D diagnosis occurs with the onset of clinical symptoms. However, the detection of islet autoantibodies can identify pre-clinical stages of disease that precede symptom onset. Stage 1 is identified by the presence of multiple islet autoantibodies with normal blood glucose levels, while stage 2 is characterized by both islet autoantibodies and abnormal blood glucose levels (dysglycemia). Finally, stage 3 represents the symptomatic onset of T1D. The mechanism leading to progression between stages is not understood and models to predict who will progress are limited.